XML 49 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 114,291 $ 140,418
Restricted cash, current portion 2,000 0
Marketable securities 240,561 259,715
Interest receivable 680 375
Accounts receivable 21,953 4,673
Prepaid expenses and other current assets 4,691 5,340
Total current assets 384,176 410,521
Marketable securities, non-current 52,789 0
Property and equipment, net 26,516 78,723
Intangible assets 51,741 54,243
Goodwill 38,270 40,044
Operating lease right-of-use assets 77,505  
Other non-current assets 7,725 3,364
Non-current restricted cash 1,500 3,500
Total assets 640,222 590,395
Current liabilities:    
Accounts payable and accrued liabilities 21,965 21,457
Accrued compensation and employee benefits 11,024 9,490
Deferred revenues 47,561 47,564
Total current liabilities 80,550 78,511
Deferred revenues, non-current 87,798 108,273
Long-term portion of lease liabilities 40,609 27,689
Deferred income tax 6,395 6,705
Other non-current liabilities 5,542 1,960
Total liabilities 220,894 223,138
Commitments and contingencies
Stockholders' equity:    
Common stock 1,158 1,022
Additional paid-in capital 1,084,372 929,632
Accumulated deficit (661,540) (562,696)
Accumulated other comprehensive loss (4,901) (1,440)
Total Sangamo Therapeutics, Inc. stockholders' equity 419,089 366,518
Non-controlling interest 239 739
Total stockholders' equity 419,328 367,257
Total liabilities and stockholders' equity $ 640,222 $ 590,395